Oral Alendronate Increases Bone Mineral Density in Postmenopausal Women with Primary Hyperparathyroidism
| Autor: | Norman N. Chan, Gary T. C. Ko, K. W. Lo, W.B. Chan, C. C. Chow, June K. Y. Li, Michael H.M. Chan, Clive S. Cockram |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
medicine.medical_specialty
Endocrinology Diabetes and Metabolism Clinical Biochemistry Administration Oral Placebo Biochemistry Endocrinology Bone Density Internal medicine Humans Medicine Aged Femoral neck Bone mineral Hyperparathyroidism Alendronate biology business.industry Alendronic acid Biochemistry (medical) Liter Middle Aged medicine.disease Postmenopause medicine.anatomical_structure Osteocalcin biology.protein Calcium Female business Biomarkers Primary hyperparathyroidism Follow-Up Studies medicine.drug |
| Zdroj: | The Journal of Clinical Endocrinology & Metabolism. 88:581-587 |
| ISSN: | 1945-7197 0021-972X |
| Popis: | The effect of biphosphonate therapy on bone mineral density (BMD) in patients with primary hyperparathyroidism (PHP) is unknown. Forty postmenopausal women (mean age, 70 yr) with PHP were randomized to receive alendronate 10 mg/d or placebo for 48 wk, followed by treatment withdrawal for 24 wk. The mean (+/-SD) changes in BMD at femoral neck (+4.17 +/- 6.01% vs. -0.25 +/- 3.3%; P = 0.011) and lumbar spine (+3.79 +/- 4.04% vs. 0.19 +/- 2.80%; P = 0.016) were significantly higher with alendronate at 48 wk. Serum calcium was reduced with alendronate but not placebo (-0.09 vs. +0.01 mmol/liter; P = 0.018). Serum bone-specific alkaline phosphatase activity was lower with alendronate from 12 wk onward and increased 24 wk after treatment withdrawal (21.1 +/- 12.8 to 7.3 +/- 4.9 IU/liter at 48 wk, and 15.0 +/- 14.8 IU/liter 24 wk after withdrawal; P = 0.002 for trend). Osteocalcin concentration decreased at 48 wk and increased 24 wk after alendronate withdrawal (P = 0.019 for trend of change over time) but not with placebo. Urinary N-telopeptide/creatinine ratio decreased with alendronate at 48 wk and increased 24 wk after treatment withdrawal (P = 0.008 for trend). N-telopeptide/creatinine ratio did not change with placebo. Alendronate improves BMD and reduces bone turnover markers in postmenopausal women with PHP. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|